Holen Sie sich die Stockscreener-App
4.66
1.53%
0.07
Handel nachbörslich:
4.71
0.05
+1.07%
Schlusskurs vom Vortag:
$4.59
Offen:
$5.05
24-Stunden-Volumen:
13.30M
Relative Volume:
3.04
Marktkapitalisierung:
$1.42B
Einnahmen:
$75.13M
Nettoeinkommen (Verlust:
$-146.41M
KGV:
-9.5024
EPS:
-0.4904
Netto-Cashflow:
$-174.43M
1W Leistung:
+12.02%
1M Leistung:
+32.39%
6M Leistung:
-0.64%
1J Leistung:
+112.79%
1-Tages-Spanne:
$4.57
$5.16
1-Wochen-Bereich:
$3.76
$5.16
52-Wochen-Spanne:
$1.94
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.66 | 1.40B | 75.13M | -146.41M | -174.43M | -0.4904 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
MSN Money - MSN
AbCellera Biologics Stock (ABCL) Opinions on Earnings and ABCL635 Phase 1 Data - Quiver Quantitative
Cantor Fitzgerald Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $7 - Moomoo
JonesResearch Reiterates Buy on AbCellera Biologics (ABCL) - Insider Monkey
5 Best Healthcare AI Stocks to Buy According to Analysts - Insider Monkey
A Look At AbCellera Biologics (ABCL) Valuation As It Prepares ABCL635 Phase 1 Interim Update - Yahoo Finance
AbCellera Biologics Among 3 Promising Penny Stocks - Yahoo Finance
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7 - Moomoo
AbCellera Biologics | ARS: Annual Report to Security Holders - Moomoo
[ARS] AbCellera Biologics Inc. SEC Filing - Stock Titan
AbCellera Biologics (NASDAQ:ABCL) Shares Down 7.6%Time to Sell? - MarketBeat
AbCellera (NASDAQ: ABCL) details 2026 vote on directors, auditor and Say-on-Pay - Stock Titan
AbCellera Biologics | DEFA14A: Others - Moomoo
AbCellera Biologics | DEF 14A: Definitive information statements - Moomoo
Jones Trading initiates coverage of AbCellera Biologics (ABCL) with buy recommendation - MSN
Leerink Partners Downgrades AbCellera Biologics (ABCL) - MSN
AbCellera Biologics Pivots to In-House Pipeline, Teases Q3 Phase II Data for ABCL635 Hot Flashes - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price & News - The Motley Fool Canada
BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7 - Moomoo
JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $11 - Moomoo
AbCellera (ABCL) Positioned Favorably Ahead of Phase 1 Update - GuruFocus
ABCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AbCellera Biologics (ABCL) Is Up 6.8% After Announcing First Human Data Timeline For ABCL635 - simplywall.st
ABCL: Lead antibody for menopausal hot flashes nears pivotal phase II data, aiming for market differentiation - TradingView
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - BioSpace
AbCellera to share Phase 1 data for menopause drug on May 11 - Investing.com Australia
JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL) - Insider Monkey
AbCellera to share Phase 1 data for menopause drug on May 11 By Investing.com - Investing.com South Africa
Press Release: AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Moomoo
10 Stocks Under $5 with Huge Upside Potential - Insider Monkey
AbCellera Biologics Inc. (ABCL): A bull case theory - MSN
AbCellera Biologics (ABCL) Committed to Leverage Differentiated Technology for Drug Discovery - MSN
AbCellera (ABCL): Among the stocks that could 10x over the next 5 years - MSN
AbCellera Biologics Inc. (ABCL) - DirectorsTalk Interviews
Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout By Investing.com - Investing.com Canada
Truist reiterates Buy on AbCellera stock ahead of 2H26 data - Investing.com
Truist reiterates Buy on AbCellera stock ahead of 2H26 data By Investing.com - Investing.com Canada
Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout - Investing.com
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating - 富途牛牛
Biotech Penny Stocks Rally OABI ABCL PACB 2026 - Gotrade
Is Jones Trading’s New Coverage of AbCellera (ABCL) Reframing Its Clinical-Stage Platform Narrative? - Yahoo Finance
Is AbCellera Biologics Inc affected by consumer sentimentWall Street Watch & Free High Return Stock Watch Alerts - baoquankhu1.vn
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):